HyQvia is a liquid medicine that is given under the skin (subcutaneously) to treat chronic inflammatory demyelinating polyneuropathy (CIDP) in adults.
![HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].](/content/experience-fragments/takeda/hyqvia/language-masters/en/site/header/header---cidp---day-90/_jcr_content/root/container_478405201_/container/image.coreimg.svg/1708016112786/hyqvia-logo.svg){kind=logo}
to support from the start
Resources to learn about HyQvia and your CIDP
There are really helpful resources available to help you learn as much as you can. Any time you have a question about your condition or HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], you should ask your healthcare team. But the resources below are a great start (or refresher)!
Welcome to Takeda Patient Support
When you’re prescribed a Takeda treatment, Takeda Patient Support is here for you. Our support specialists can get you enrolled, address your questions and concerns, and help you get the answers, resources and tools you need. We can also:
- Work with your specialty pharmacy (or site of care) to help you receive your prescribed Takeda treatment
- Connect you to co-pay or insurance help,* and more
*For commercial patients only.
Learning about financial assistance options
Whether you have commercial insurance, have government insurance, or are uninsured, our support specialists can answer your questions and help you understand what financial assistance options may be available.
Have commercial insurance?
We can direct you to programs that may help you save on your treatment, if you’re eligible.
The Takeda Patient Support Co-Pay Assistance Program can cover up to 100% of your out-of-pocket co-pay costs, if you’re eligible.†‡ To be eligible for this program, you must:
Be prescribed HyQvia for a condition it’s approved to treat by the Food and Drug Administration (FDA). This is called an “approved indication.” Ask your healthcare provider if you’re not sure.
Have commercial insurance. This includes Health Insurance Marketplace plans
- Commercial insurance does not include Medicare, Medicaid, Veterans Affairs (VA), or other federal or state health plans
Be enrolled in Takeda Patient Support.
†Additional Terms and Conditions apply.
‡IMPORTANT NOTICE: Takeda’s Co-pay Assistance Program ("the Program") provides financial support for commercially insured patients who qualify for the Program. Participation in the Program and provision of financial support is subject to all Program terms and conditions, including but not limited to eligibility requirements, the Program maximum benefit per claim and the annual calendar year Program maximum (“Annual Program Maximum”). The Annual Program Maximum for your prescribed Takeda product can be found by visiting: www.takedapatientsupport.com/copay.
By enrolling in the Program, you agree that the Program is intended solely for the benefit of you—not health plans and/or their partners. Further, you agree to comply with all applicable requirements of your health plan. The Program cannot be used if the patient is a beneficiary of, or any part of the prescription is covered by: 1) any federal, state, or government-funded healthcare program (Medicare, Medicare Advantage, Medicaid, TRICARE, etc.), including a state pharmaceutical assistance program (the Federal Employees Health Benefit (FEHB) Program is not a government-funded healthcare program for the purpose of this offer), 2) the Medicare Prescription Drug Program (Part D), or if the patient is currently in the coverage gap, or 3) insurance that is paying the entire cost of the prescription. No claim for reimbursement of the out-of-pocket expense amount covered by the Program shall be submitted to any third-party payer, whether public or private.
Some health plans have established programs referred to as ‘co-pay maximizer’ programs. A copay maximizer program is one in which the amount of a patient’s out-of-pocket costs is adjusted to reflect the availability of support offered by a manufacturer’s co-pay assistance program. If you are enrolled in a co-pay maximizer program, your Annual Program Maximum may vary over time to ensure the program funds are used for your benefit (for the benefit of the patient). Takeda also reserves the right to reduce or eliminate the co-pay assistance available to patients enrolled in an insurance plan that utilizes a co-pay maximizer program.
If you learn your health plan has implemented a co-pay maximizer program, you agree to notify the Program immediately by calling 1-866-861-1750. It may be possible that you are unaware whether you are subject to a co-pay maximizer program when you enroll or re-enroll in the Program. Takeda will monitor program utilization data and reserves the right to discontinue assistance under the Program at any time if Takeda determines that you are subject to a co-pay maximizer, or similar program.
The Program only applies in the United States, including Puerto Rico and other U.S. territories, and does not apply where prohibited by law, taxed, or restricted. This does not constitute health insurance. Void where use is prohibited by your insurance provider. If your insurance situation changes you must notify the Program immediately by calling 1-866-861-1750. Coverage of certain administration charges will not apply for patients residing in states where it is prohibited by law.
This Program offer is not transferable and is limited to one offer per person and may not be combined with any other coupon, discount, prescription savings card, rebate, free trial, patient assistance, co-pay maximizer, alternative funding program, co-pay accumulator, or other offer, and including those from third parties and companies that help insurers or health plan manage costs. Not valid if reproduced.
By utilizing the Program, you hereby accept and agree to abide by these terms and conditions. Any individual or entity who enrolls or assists in the enrollment of a patient in the Program represents that the patient meets the eligibility criteria and other requirements described herein. You must meet the Program eligibility requirements every time you use the Program. Takeda reserves the right to rescind, revoke, or amend the Program at any time without notice, and other terms and conditions may apply.
Can’t afford your treatment?
If you do not have insurance or are experiencing a loss of or lapse in coverage, our support specialists may be able to connect you to programs that may help.
Not enrolled?
You can join Takeda Patient Support in a few simple steps at TakedaPatientSupport.com
If English is not your preferred language, let us know. We can assist you in a language of your choosing.
FREE TRIAL PROGRAM
See if HyQvia is right for you with this free trial
With HelloHYQVIA, the entire cost of your first three infusions of HyQvia, along with the supplies needed for administration, is covered. Your doctor can take the first step to enroll you, so be sure to ask! This free trial offer is solely intended to allow eligible patients to try HyQvia and to determine with their doctor whether HyQvia is right for them. There is no obligation for the patient to continue use of HyQvia after the free trial has been completed.
To be eligible for the HelloHYQVIA program, patients must:
- Be an adult patient with an ICD-10-verified diagnosis of CIDP
- Be a new patient not currently using HyQvia and who has not previously enrolled in the HelloHYQVIA program. Additional terms and conditions apply
Download the HelloHYQVIA free trial brochure to learn more about the program.
Support materials
HyQvia Experience & Symptom Tracking Guide
Keep track of your treatment and questions. Here, you’ll keep a record of each infusion and its details, and jot down any thoughts, questions, or notes about your infusion experience for yourself or to remember when following up with your doctor.
Before you talk to your doctor, fill out the doctor discussion guide
Have a conversation about your treatment routine? Do you like it? What would you change? It’s good to talk these things through with your doctor because they may point out something you haven’t thought of that could make your routine more tailored to you. This checklist can help. Download this guide and fill it out so you can bring it to your next appointment.
HyQvia Consideration Brochure
Get familiar with HyQvia, what it is, and how it works. The perfect place to start if you’re considering HyQvia.
Patient Starter Kit
Takeda provides Patient Starter Kits to specialty pharmacies. The kits are designed to help educate patients about infusing HyQvia and should be sent along with their infusion system. The kit does not replace training by a healthcare provider. Includes Overview Guide, Step-by-Step Infusion Guide, Wellness Journal, and Infusion Mat.
Welcome to HyQvia
This video walks you through all the contents of your HyQvia Starter Kit.
COMMUNITY SUPPORT
Have you checked out these organizations?
Their missions are to help you understand everything from diagnosis to clinical research and so much more.
The Foundation for Peripheral Neuropathy strives to cure painful neuropathies through collaborative research, education, and treatment.
The GBS | CIDP Foundation International is a global nonprofit organization supporting individuals and their families affected by Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), and related conditions through a commitment to support, education, research, and advocacy.
The NAF is dedicated to ensuring neuropathy patients obtain the necessary resources, information, and tools to access individualized treatment to improve their quality of life.
FAQS
Chances are, if you’re thinking of it, others have too
You should always talk to your doctor or someone from your healthcare team first. Those conversations are the best way to get answers, but here’s a list of frequently asked questions.
HyQvia is an IG + Hy therapy that can help prevent CIDP relapses in adult patients.
HyQvia is a maintenance therapy. This means when you’re first diagnosed with CIDP, you may start on an IVIG therapy to get your symptoms under control. Once your symptoms are under control followed by stable doses of IVIG, your doctor may prescribe a maintenance therapy like HyQvia to help prevent relapse. Learn more about HyQvia.
HyQvia is an IG + Hy therapy that can help prevent CIDP relapses in adult patients.
HyQvia is administered every 2, 3, or 4 weeks to help prevent relapse. In clinical trials, most patients received HyQvia every 4 weeks. Talk with your doctor about what dosing schedule may be best for you. As demonstrated in the clinical trial, 14.0% (8/57) of patients treated with HyQvia experienced a relapse compared with 32.3% (21/65) of patients treated with placebo. The most common ARs were local reactions, headache, vomiting, fatigue, nausea, fever, itching, redness, abdominal pain, back pain, and pain in extremity. Learn more.
Recombinant Human Hyaluronidase temporarily opens the space under your skin (the subcutaneous space), allowing a larger amount of immune globulin to reach your subcutaneous tissue, which helps more of the immune globulin get absorbed under the skin. See how HyQvia works.
HyQvia is the only IG therapy that combines IG with hyaluronidase, Hy. The IG in HyQvia is thought to reduce damage to the nerves and assist in defending the nerves from harm. HyQvia is similar to the IG in IVIG therapies. The Hy helps your body take in and disperse a larger amount of IG, which is why HyQvia can be infused monthly.*
*Every 2, 3, or 4 weeks.
AR=adverse reaction; CIDP=chronic inflammatory demyelinating polyneuropathy; ICD-10=International Classification of Diseases, Tenth Revision; Hy=hyaluronidase; IG=immune globulin; IVIG=intravenous immune globulin.
©2024 Takeda Pharmaceuticals U.S.A., Inc., 300 Shire Way, Lexington, MA 02421. 1-877-TAKEDA-7 (1-877-825-3327). All rights reserved. TAKEDA®, the TAKEDA Logo®, and the TAKEDA Patient Support Logo™ are trademarks or registered trademarks of Takeda Pharmaceutical Company Limited. HYQVIA® and MYIGSOURCE™ are trademarks or registered trademarks of Baxalta Incorporated.
US-HYQ-1272v1.0 06/24
See you later!
We hate to part, but you’re now leaving this site and being redirected to a site not owned or managed by Takeda.
See you later!
We hate to part, but you're now leaving this site and being redirected.